NTRA
Natera, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth +4.5% ·
share flow +0.5% ·
net new positions 0.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 6 | 0 | 535.21K | $217.82M | n/a | n/a |
| Q2 2026 | 162 | 0 | 104.13M | $28.25B | +5 | −4 |
| Q1 2026 | 164 | +3 | 98.65M | $19.54B | +6 | −4 |
| Q4 2025 | 160 | 0 | 102.31M | $23.44B | +1 | n/a |
| Q3 2025 | 23 | +1 | 81.70M | $13.15B | +1 | −1 |
| Q2 2025 | 20 | -1 | 57.32M | $9.68B | n/a | −1 |
| Q1 2025 | 18 | 0 | 31.15M | $4.40B | n/a | n/a |
| Q4 2024 | 18 | 0 | 26.97M | $4.27B | n/a | n/a |
| Q3 2024 | 17 | -1 | 21.42M | $2.72B | n/a | −1 |
| Q2 2024 | 18 | n/a | 16.29M | $1.76B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | JPMorgan Chase ✦ | 23.26M | n/a | $3.74B | 0.1% | n/c | 1 | SEC ↗ ×34 |
| 2 | The Vanguard Group ✦ (passive) | 12.39M | -2.3% | $1.99B | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | T. Rowe Price ✦ | 11.95M | -2.0% | $1.92B | 0.2% | ▼ Trim | 6 | SEC ↗ ×2 |
| 4 | BlackRock ✦ (passive) | 10.96M | +0.1% | $1.76B | 0.0% | ▲ Add | 2 | SEC ↗ ×22 |
| 5 | State Street Global Advisors ✦ (passive) | 3.39M | +2.2% | $545.62M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Duquesne Family Office ✦ | 3.21M | +4.2% | $517.44M | 13.2% | ▲ Add | 6 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 2.60M | +1.7% | $417.63M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 2.56M | -3.0% | $411.45M | 0.1% | ▼ Trim | 6 | SEC ↗ ×8 |
| 9 | AQR Capital Management ✦ | 2.40M | +39.0% | $386.34M | 0.2% | ▲ Add | 6 | SEC ↗ ×7 |
| 10 | Capital World Investors ✦ | 1.41M | +0.2% | $227.41M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 11 | Morgan Stanley ✦ | 1.28M | n/a | $206.58M | 0.0% | n/c | 1 | SEC ↗ ×13 |
| 12 | Fidelity (FMR) ✦ | 1.11M | -23.4% | $179.22M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 13 | Goldman Sachs Group ✦ | 1.10M | n/a | $177.31M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Citadel Advisors ✦ | 896.67K | +9.2% | $144.34M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 15 | ARK Investment Management ✦ | 892.59K | -4.7% | $143.68M | 0.9% | ▼ Trim | 6 | SEC ↗ |
| 16 | Arrowstreet Capital ✦ | 558.99K | +15.7% | $89.98M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 17 | Millennium Management ✦ | 527.94K | +199.1% | $84.98M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 18 | Renaissance Technologies ✦ | 298.50K | -39.5% | $48.05M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 281.57K | +11.5% | $45.32M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 20 | Point72 Asset Management ✦ | 238.96K | +1.7% | $38.47M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 21 | Coatue Management ✦ | 170.33K | New | $27.42M | 0.1% | New | 1 | SEC ↗ ×7 |
| 22 | D. E. Shaw & Co. ✦ | 132.16K | -24.0% | $21.27M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 23 | Gotham Asset Management ✦ | 71.63K | -29.5% | $11.53M | 0.1% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Coatue Management | $27.42M | 0.1% |
Exited
| Norges Bank | $277.75M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 755 holders, 120.14M shares, $20.15B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 627 sh · $257,003
Director · 605 sh · $248,847
Director · 962 sh · $392,745
Director · 125 sh · $51,631
Director · 211 sh · $86,974
Director · 255 sh · $105,995
Director · 165 sh · $68,751
Director · 200 sh · $81,300
Director · 80 sh · $32,484
Director · 50 sh · $20,258
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology